Gliomas represent the most frequent type of human brain tumor, and their strong invasiveness is a significant clinical problem. Microglia, the immunocompetent cells of the brain, contribute significantly to the tumor and are potential interaction partners of the glioma cells. We studied the impact of the presence of microglia on tumor cell invasion in cultured brain slices. To selectively deplete microglia, the slices were treated with clodronate-filled liposomes. When glioma cells were injected into slices devoid of endogenous microglia, the invasiveness of the tumors was significantly decreased as compared with controls. Inoculation of exogenous microglia together with glioma cells into cultured brain slices increased the infiltrative behavior of the tumor depending on the microglia/glioma cell ratio. Cell culture experiments revealed that soluble factors released from glioma cells strongly stimulate metalloprotease-2 activity in microglia. In the brain slices inoculated with glioma cells, increased activity of metalloprotease-2 was directly correlated with the abundance of microglia. Our data indicate that glioma cells stimulate microglial cells to increase breakdown of extracellular matrix and thereby promote tumor invasiveness.
INTRODUCTION
Glioblastomas are the largest group of primary brain tumors, affecting between 15,000 and 20,000 individuals per year in the United States alone. These tumors are characterized by their morphologically and genetically complex nature and by their diffuse infiltration deep into the brain parenchyma (1) . The diversity in morphologic appearance and the extreme invasiveness of gliomas are the major obstacles for efficient surgical resection (2) . Therefore, standard treatments such as surgery, radiation therapy, and chemotherapy only improve mean survival of gliomas by 2 to 3 months to an average survival of 1 year after diagnosis. Matrix degradation by metalloproteases (MMPs) is a key feature in mediating the malignant characteristics of gliomas (3) . In human brain tissue samples, MMP-2 and MMP-9 were detected, and especially the activity of MMP-2, has been directly correlated with the malignancy of brain tumors (4) .
Glioma expansion is not stopped by the immune response, although these tumors consist of 34% microglia on average (5) . Microglial cells are the resident macrophages of the brain, which can quickly respond to a whole range of pathologic stimuli (6) . Microglia exert an important neuroprotective role, for example, by phagocytosing cellular debris after tissue injury and as antigen-presenting cells in the adaptive immune response. On the other hand, misregulation of the inflammatory response of microglia is neurotoxic and is considered to contribute to the progress of various brain pathologies such as HIV dementia, Alzheimer disease, and multiple sclerosis (7) . Gliomas can actively suppress antitumorigenic activity of microglia (8) . The immune-suppressed microglia may even have tumor-promoting features (5, 9) . Indeed, microglia stimulated the motility of cultured glioma cells in a Boyden chamber assay (10) . We have addressed the question of whether the presence of microglia can influence the invasion of glioma cells in brain tissue and have obtained evidence that microglia promote the invasiveness of gliomas by increasing the activity of the proinvasive enzyme MMP-2.
MATERIALS AND METHODS

Glioma Cell Lines
The F98 cell line was obtained from American Type Culture Collection (Manassas, VA), and the GL261 cells lines were purchased from National Cancer Institute (NCI, Frederick, MD). F98 and GL261 glioma cells were grown in Dulbecco modified eagle medium (DMEM; Gibco, Gaithersburg, MD) with 10% heat-inactivated fetal calf serum (Atlanta Biologicals, Norcross, GA), 0.2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin in 250-mL tissue culture flasks (Falcon model 3023; Becton Dickinson, Lincoln Park, NJ). The rat F98 cell line was selected because of its high basal motility rate in vitro, and the mouse GL261 cell line was selected because it was isogenic to the donor animals for obtaining brain slices. The medium was changed every 2 days and cells were passaged when the cell density in the flask reached confluency. Cell cultures were maintained at 37°C in humidified 5% CO 2 /95% air incubator (Heraeus, Hanau, Germany).
Microglial Cell Culture
Microglial cultures were prepared from cerebral cortex of newborn C57/Bl6 mice as described previously (11) . In brief, the forebrain was carefully freed of blood vessels and meninges. Cortical tissue was trypsinized for 2 minutes, dissociated with a fire-polished pipette, and washed twice. Mixed glial cells were cultured for 9 to 12 days in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin with medium changes every third day. Microglial cells were then separated from the underlying astrocytic layer by gentle shaking of the flask for 1 hour at 37°C in a shaker-incubator (100 rpm). The cells were seeded in 6-well plates at a density 10 6 cells/well, respectively. Cultures usually contained . 95% microglial cells, which could be stained with Griffonia simplicifolia isolectin B4 (Sigma Aldrich, Deisenhofen, Germany), a marker for microglia. Cultures were used for experiments 1 to 5 days after plating. Cell media and supplements were purchased from Seromed/Biochrom (Berlin, Germany).
Glioma Transfection
F98 and GL261glioma cells were transfected with the pEGFP-N1 vector for expression of enhanced green fluorescent protein (EGFP; Clontech, Heidelberg, Germany) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The p-EGFP-N1 vector contains the human cytomegalovirus promoter, which drives high-level expression of the EGFP in transfected cells. Using Genetecin-G418 (Gibco) selection, 1.2 mg/mL in the case of F98 and 600 mg/mL for GL261 stable clones of transfected F98 and GL261 glioma cells were obtained. Viable cells with bright fluorescence were selected by fluorescence-activated cell sorting. On the day of injection, between 90% and 95% of cells were fluorescently labeled.
Organotypical Brain Slice Model
The procedure to establish organotypical brain slice cultures is a modification of previously published protocols (12) (13) (14) (15) (16) . Brain tissue was derived from 16-day-old male C57BL/6 mice (animal breeding facility, Schönwalde, Germany) and from transgenic mice expressing EGFP under a promoter for glial fibrillary acidic protein (EGFP-GFAP mice [17] ). For organotypical brain slice preparations, mice were decapitated and the brain was removed within 2 to 3 minutes and placed in ice-cold (4°C) phosphate-buffered saline (PBS) under sterile conditions. The forebrain was dissected from the brainstem and glued (using cyanoacrylate glue) onto a glass block and cut in the coronal plane into 250-mm sections with a vibratome (Leica VT1000S; Leica Co., Heidelberg, Germany). The brain slices were transferred onto the 0.4-mm polycarbonate membrane in the upper chamber of a transwell tissue insert (Falcon model 3090; Becton Dickinson), which was inserted into a 6-well plate (Falcon model 3502; Becton Dickinson). Thereafter, the brain slices were incubated in 1 mL of culture medium per well containing DMEM supplemented with 10% heatinactivated fetal bovine serum (Atlanta Biological), 0.2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (medium-1). After overnight equilibration of the brain slices in medium-1, this was exchanged for cultivation medium (medium-2). Medium-2 contained 25% heat-inactivated horse serum, 50 mM sodium bicarbonate, 2% glutamine, 25% Hank's balanced salt solution, 1 mg/mL insulin (all from Gibco), 2.46 mg/mL glucose (Braun Melsungen, Germany), 0. 8 mg/mL vitamin C (Sigma Aldrich), 100 U/mL penicillin, 100 mg/mL streptomycin (Sigma Aldrich), and 5 mM Tris in DMEM (Gibco).
Tumor Cell Injection Into Brain Slices
Approximately 5000 F98 or GL261 tumor cells in a volume of 0.5 mL were inoculated into the slices using a syringe mounted to a micromanipulator. This device allowed placement of the tip of the syringe consistently at the same defined region on the slice surface. An injection canal was formed that reached 150 mm deep into the 250-mm-thick slice. The needle was then retracted by 50 mm, leaving an injection cavity of approximately 50 mm. The cell suspension was slowly injected over 30 seconds and subsequently the syringe was slowly pulled out in 10-mm incremental steps over 60 seconds. To ensure identical experimental conditions, the gliomas were always inoculated into the same area. Directly after glioma injection, the tumor cells remained at the inoculation site, which could therefore mark the point of origin for all further movements of these cells. Careful control of the injection procedure ensured that no cells spilled onto the surface of the slices, which could migrate over the surface rather than invade through the tissue.
Liposomes
Clodronate-loaded liposomes were obtained from GOT Therapeutics (Berlin, Germany) and from the Department of Molecular Cell Biology of the Free University of Amsterdam. For the preparation of clodronate liposomes, 86 mg of phosphatidylcholine (Lipoid EPC; LIPOID, Ludwigshafen, Germany) and 8 mg of cholesterol (Sigma, St. Louis, MO) were combined with 10 mL of a clodronate (0.7 molar; a gift of Roche Diagnostics, Mannheim, Germany) solution and sonicated gently. The resulting liposomes were then washed to eliminate free drug. For control experiments, PBS-filled liposomes and carboxyfluorescein-loaded liposomes were prepared under the same conditions. All liposomes were passed through a 12-mm filter immediately before use to eliminate large lipid aggregates (18) .
Confocal Microscopy
2 Photon microscopy (Till Photonics, Muenchen, Germany) was used to study the distribution of glioma cells at the inoculation site. Evaluation of the 3-dimensional distribution of the glioma cells revealed that the tumor cells were consistently inserted into the central part of the 250-mm-thick slices (thereby excluding the possibility that glioma cells spilled onto the surface of the brain slice during the inoculation procedure). Hence, all glioma cells investigated for their migratory patterns invaded through the core of the slices and did not migrate on the surface of the cultures. Migratory distances were then investigated using a confocal microscope (Sarastro 2000; Molecular Dynamics, Sunnyvale, CA).
Immunofluorescence
All staining was performed on the whole-brain slice cultures and the primary antibodies were applied overnight in the TBS buffer (100 mM Tris and 150 mM NaCl) containing 1% Tx-100 and 3% donkey serum. We used the following primary antibodies: rabbit anti-Iba-1 (Wako, Japan), rabbit anti-GFAP (DAKO Cytomation, Glostrup, Denmark), goat anti-GFP (Acris Antibodies, Hiddenhausen, Germany), rabbit antineurofilament 200 kDa (NF-200), and rabbit anti-von Willebrand factor (both from Chemicon, Temecula, CA). FITC and Rhodamine red conjugated secondary antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA).
Gelatin Zymography
Activity of gelatinases (MMP-2 and MMP-9) was analyzed with the gelatin zymography procedure (19) . Briefly, conditioned media from organotypical brain slice cultures or cell cultures or whole slice cultures were mixed with sample buffer (0.5 M Tris, pH 6.8; 20% glycerol, 4% SDS, 0.1% Tx-100) and the samples were loaded into 7.5% SDS-gel containing 1% gelatin. After electrophoresis (4°C, 90 V) gel was washed 2 3 15 minutes in 2.5% Tx-100 washing solution and incubated overnight in developing buffer (50 mM Tris, pH 7.6; 10 mM CaCl 2 ; 50 mM NaCl; 0.05% Brij 35). Next, the gel was stained for 30 minutes in 0.5% Coomassie blue solution and later destained with 40% methanol and 10% acetic acid. Gelatinase activity resulted in clear bands on dark blue background and this activity could be quantified. Gelatinase types were identified by molecular weight markers.
Statistical Analysis
Statistical analyses were performed using SPSS (SPPS Inc., Chicago, IL) software. Statistical significance was determined at the p , 0.05 level. The results are expressed as mean 6 standard errors of the mean (SEM). Comparisons among the groups were performed with the paired samples t-test and the Wilcoxon signed-rank test.
RESULTS
Slice Cultures Were Selectively Depleted of Microglia
To study the impact of microglia on tumor invasion, we developed a protocol to deplete microglia from organotypic brain slice cultures (Fig. 1A) . This method allowed us to inoculate glioma cells into microglia-free tissue and compare their invasive potential with control tissue. In untreated control slices, microglial cells were evenly distributed within the tissue when inspected 96 hours after plating (Fig. 1B) , as demonstrated by immunolabeling with Iba1 (monocyte and macrophage marker) antibodies. The microglia exhibited mainly ameboid and to a lesser extent ramified morphology ( (Fig. 1C) . Application of liposomes filled with buffer alone (PBS liposomes) did not lead to a depletion of microglia under identical experimental conditions (data not shown). We observed, however, an uneven distribution of Iba 1-positive cells in a vertical section of the slice tissue. Within 24 hours, microglial cells accumulated close to the surface of the brain slice and were amassed around blood vessels.
Astrocytes and Neurons Were Not Affected by Clodronate Treatment
To test the impact of the clodronate liposome treatment on neurons and astrocytes, we used GFAP-EGFP transgenic animals in which astrocytes were expressing EGFP, and GFAP and neurofilament-200 immunocytochemistry were used to identify astrocytes and neurons. EGFP expression in brain slices from GFAP-EGFP transgenic mice under control conditions was low but increased significantly within the first 24 hours after clodronate liposome treatment, indicating that the astrocytes within the slice preparations survived the clodronate treatment without any attenuation of their ability to respond to external stimuli. Seventy-two hours after treatment with clodronate liposomes (96 hours in culture), control and treated slices were indistinguishable with respect to GFAP expression (data not shown). We therefore inoculated the slices 72 hours after clodronate liposome treatment to avoid any influence of reactive astrocytes on our tumor implants. After 96 hours in culture, there were no detectable differences in GFAP expression and cell morphology in whole brain sections of control or clodronate liposome-treated slices (Fig. 1D, E) . Neuronal labeling by neurofilament-200 after 96 hours in culture did not differ in control versus clodronate liposometreated slices as revealed by confocal microscopy of brain slices (Fig. 1F, G) .
Tumor Cell Migration Can Be Quantified After Inoculation into Slices
To establish a reproducible model for tumor cell invasion, approximately 5000 EGFP transfected F98 or GL261 tumor cells were inoculated into the slices (Fig. 2A) . Two hours after injection, the EGFP-labeled glioma cells were concentrated no more than 300 mm from the injection canal (n = 8, not shown). An example from a single experiment is shown in (Fig. 2B-F) . Over a time course of 5 days, we observed and quantified the movement of glioma cells migrating away from the injection site. The slices flattened during the culture period to a thickness of approximately 150 mm, and the highest glioma cell density was in the center of the slice. To evaluate tumor cell invasion, slices were fixed in paraformaldehyde and inspected by confocal and 2-photon microscopy. We measured the distance between the individual fluorescent cells and the center of the injection canal (Fig. 2E) . Accumulated data from up to 600 cells per injection site allowed us to assemble distance histograms (Fig. 2F ).
Experimental Gliomas in Cultured Brain Slices Share Features with Human Glioblastomas
First, we evaluated whether our experimental model exhibited associations of microglia with glioma cells that were similar to those reported for human glioblastomas. Second, we studied which invasion pattern the glioma cells would show in our model, that is, if the glioma cells invaded as single cells or as cell clusters and if they diffusely infiltrated the parenchyma or progress along blood vessels. Four days after implantation, microglia had infiltrated the tumors and aggregated in a large number around tumors (as determined by labeling with the microglia marker Iba 1; Fig. 2G ). At this time point, the highly invasive glioma cells, which are distant to the injection site, are either found as single cells or as groups of a few cells within the parenchyma (Fig. 2G, H) . Labeling with the endothelial cell marker von Willebrand factor revealed that a fraction of glioma cells was closely associated with blood vessels (Fig. 2H) .
Glioblastoma Cell Invasion Was Impaired in Microglia-Depleted Slices
We compared tumor cell migration in untreated control slices, slices treated with PBS-filled liposomes, and microgliadepleted slices at days 2, 4, and 5 after F98 or GL261 cell injection. Two days after injection, the bulk population of glioma cells formed a mass of approximately 500 mm in radius and only few cells dispersed out of this mass (Fig. 3A) . To get a measure of the migratory potential of the tumor cells, we arbitrarily defined 2 cell populations. A first population, which stayed within a radius of 500 mm to the tumor center, was regarded as resident cells. A second cell population, which had migrated beyond that radius, was referred to as invasive cells. At day 2 after tumor inoculation, there was no significant difference in migratory distances in untreated compared with microglia-depleted slices. The distribution of GL261 cells throughout the brain slices in control and clodronate liposometreated slices were similar (Fig. 3A, D) . In control slices, only 9% of cells migrated more than 500 mm compared with microglia-depleted slices, where 12% of GL261 cells migrated more than 500 mm (Fig. 3D) . Similarly, 19% F98 glioma cells had migrated more than 500 mm in normal slices and 12% in microglia-depleted slices (Fig. 3E) . Four days postinoculation, the difference in migratory distances in normal and microgliadepleted slices became apparent with both cell lines. With GL261 cells, 44% migrated more than 500 mm in untreated slices and 33% in microglia-depleted slices (Fig. 3B, D) . The population of F98 cells that migrated more than 500 mm consisted of 52% in control slices and 23% in microgliadepleted slices (Fig. 3E) . Five days after inoculation, the difference in invasiveness of glioma cells between microgliadepleted and nondepleted groups remained (Fig. 3C) . In untreated slices, 67% of GL261 and 66% of F98 cells invaded more than 500 mm (Fig. 3D, E) . In microglia-depleted slices, the population of invasive cells was significantly lower: 43% of GL261 and 49% of F98 migrated more than 500 mm (Fig.  3D, E) . Hence, both glioma cell lines revealed decreased invasiveness in the microglia-depleted slices as compared with control.
In slices treated with PBS-filled liposomes, we observed a migratory behavior for both cell lines that was consistently in between the values obtained for microglia-depleted and control slices (not shown). This intermediate invasiveness is probably the result of accumulation of microglia in some areas of the slices (e.g. around blood vessels and at the edges of the slice), which left other regions of the slices largely depleted of microglia, as described previously.
Coinjection of Microglia and Gliomas Promoted Invasion of Glioma Cells
To further establish that microglia promote tumor migration, we coinjected microglia with the glioma cells into cultured slices. Five days after inoculation, we compared slices containing 5,000 GL261 cells with those in which 5,000 GL261 cells were coinjected with 5,000 microglial cells. In control slices, 33% remained within 500 mm from the injection canal (Fig. 4A) , whereas in slices coinjected with microglia, only 17% remained (Fig. 4B) . Moreover, we observed a substantially elevated fraction of tumor cells invading very far (1,500 mm and more) into the brain slice preparation.
We also compared the impact of coinjected microglia on glioma migration in microglia-depleted slices. The fraction of invading glioma cells was again lower in clodronate liposometreated slices (44% [ Fig. 4C ] compared with 67% in nondepleted slices [ Fig. 4A]) . Only a few cells migrated beyond 1500 mm. When microglia was added together with glioma cells into previously depleted slices, 75% of the glioma cells were found beyond 500 mm and we also found significantly more cells beyond 1500 mm (Fig. 4D, E) . These experiments indicate that microglial cells promote tumor invasion.
Glioma-induced MMP-2 Activity Was Elevated in Slices Containing Microglia
To monitor the activity of the metalloproteinases MMP-2 and MMP-9, extracts from cultured brain slices were analyzed in gelatin-zymography. In slices inoculated with glioma for 5 days, prominent bands indicating proteolytic activity of MMPs were consistently observed at approximately 65 kDa (Fig. 5A) , whereas only faint bands appeared in the range of approximately 92 kDa (not shown), demonstrating that the major activity was the result of MMP-2 and not MMP-9. In glioma-inoculated slices depleted of microglia, the activity of MMP-2 was considerably lower as compared with controls (Fig. 5A, left panel) . In a different experiment, we added exogenously cultured microglia together with the tumor into (microglia containing) brain slices. The MMP-2 activity in these slices was profoundly elevated as compared with slices receiving glioma injection only (Fig. 5A, right panel) .
Next, we investigated the levels of MMPs, which were secreted from tumor-bearing brain slices containing different densities of microglial cells. Supernatant from slice cultures 5 days after glioma inoculation was harvested and assayed in the zymogram. Control slices without tumors displayed a baseline level of MMP-2 activity, which was substantially increased in slices inoculated with GL261 cells (Fig. 5B) . However, in microglia-depleted slices inoculated with glioma, proteolysis by MMP-2 dropped to baseline levels. Finally, the density of microglia in the tumor parenchyma was elevated above control levels by inoculating exogenously cultured microglia together with GL261 cells into brain slices. This resulted in MMP-2 activity above baseline levels and was also considerably elevated as compared with slices containing tumors and normal density of microglia (Fig. 5B) . As described for zymograms from whole slice extracts, faint bands displaying activity for MMP-9 were visible in those samples where microglia was present (not shown).
A Soluble Factor from Glioma Triggers the Activation of MMP-2 in Cultured Microglial Cells
To investigate for a crosstalk between glioma and microglial cells influencing MMP-2 activity, we used a cell culture system in which GL261 cells were stimulated with microglia-conditioned medium and vice versa. After overnight incubations, the cells were washed and media were changed to serum-free conditions, leaving the cells to liberate active MMP into the fresh medium. Prominent bands for active MMP-2 (at 65 kDa) and for pro-MMP-2 (at 72 kDa) were visible in zymograms from supernatants of unstimulated GL261 cells. This release activity by GL261 cells was not affected by microglia-conditioned medium (Fig. 5C ). Proteolysis by soluble MMP-2 released from microglial cells, which were kept under control conditions (not stimulated with GL261-conditioned medium), appeared to be at the detection limit of the zymogram assay. However, when microglia was incubated with glioma-conditioned medium, the MMP-2 activity was strongly increased. Whereas zymograms from supernatants of GL261 cells showed bands for pro-MMP-2 and for activated MMP-2 under both experimental conditions, stimulation of microglia resulted in the elevation of a very faint band for pro-MMP-2 and of a strong band for active MMP-2 (Fig. 5C ).
DISCUSSION
The clodronate-liposome assay is an efficient tool to deplete microglia in cultured brain slices and was already successfully used for cultured cerebellar slices (20) . The brain slice model that we characterized here does not resemble all characteristics of the normal brain, and we are aware that this model is in some respect quite artificial. For example, in our model, there is no initiation of an adaptive immune response driven by T-cells coming in from the periphery. The importance of the infiltration of CD8 + T-cells was previously demonstrated in an in vivo model (21) . With respect to the invasion pattern, all rodent invasion models have some limitations; like here, clusters of glioma cells mainly invade along white matter tracts and along blood vessels (22) . However, the relevant invasion mechanism for human gliomas is single cell invasion (2) . In our model, we observe both single cell invasion and the progression of clusters of glioma cells through the parenchyma. These types of invasion took place along blood vessels and in the vessel-free parenchyma. However, we can demonstrate that our model is well suited to study the invasion of glioma cells, which need to travel centrally through the brain slices and thereby invade an intact cytoarchitecture and a natural extracellular matrix.
Our immunocytochemical characterization of the brain slices indicates no significant cellular degeneration even in the center of the slice or even after weeks of cultivation. Astrocytes show full viability and can even be activated by the microglia depletion procedure, subsequently returning to a resting state. The vitality of microglia within control slices is evident by their characteristic morphology and sustained mobility. Neurons remain largely intact; only at the surface of the brain slices, where fibers are cut during the slice preparation, was some budding of the nerve fibers observed. The neuronal fibers in the middle of brain slice culture stay intact and display no pathologic morphology. Finally, the high degree of homogeneity of the migration pattern of glioma cells within each experimental group (evidenced by the low standard deviations) indicates that the brain slice cultures represent a reproducible and reliable experimental model to study cell-cell interactions and the progression of invading tumor cells after matrix degradation.
Importantly, the use of a glioma cell line (GL261), which is syngenic with the genetic background of our mouse model (C57/Bl6), enabled us to study the impact of tumor/immunecell interactions without initiation of additional host defense mechanisms. Certainly, it allows us to do experiments that cannot be done in vivo, and it is closer to reality as compared with previously used monolayer culture models.
At the invasive edge of the tumors, we found glioma cells with the stretched morphology reminiscent of migratory cells, which progressed into the parenchyma either as single cells or as clusters of cells. The invading glioma cell clusters and individual glioma cells were partly associated with blood vessels. Additionally, we also detected single tumor cells and tumor cell aggregates that displayed a migratory phenotype and which were not found in proximity to any vessels. Therefore, the invasion pattern of glioma cell lines in our model exhibits some similarities to gliomas in humans (i.e. diffuse invasion of single cells through the brain parenchyma [22] ). We also observed a type of invasion that is apparently typical for rodent glioma cells, namely the progression of glioma cell clusters along vessels. Regardless of the invasion pattern of the glioma cells, we always observed a close association of microglial cells with the infiltrating tumor cells. This is similar to the situation in human pathology, like microglia, infiltrate the glioma cell mass (23, 24) . The amount of microglial cells found within human gliomas can vary from approximately 10% to approximately 34% (23, 24) . However, in some human gliomas, the microglia primarily associate with the glioma cells at the invasion edge of the tumors; therefore, even lower microglia cell numbers could efficiently promote glioma invasion. It was reported that in human gliomas, the expression of MMP-2 was increased at the invasive edge (25, 26) . In the present study, we demonstrated that microglia promote the activity of MMP-2 and the invasiveness of gliomas, suggesting that the progression of human tumors is boosted after interaction with the brain parenchyma, that is, with the microglia.
Microglia Promote Tumor Invasion
Our results indicate that the density of microglia in the tissue impacts glioma invasion as follows: 1) microgliadepleted slices show the lowest invasive potential of glioma; 2) addition of microglia to the depleted slices restores the invasive potential to the level of control slices; 3) coinjection of glioblastoma cells with microglia into control slices led to the highest invasion activity; and 4) the nontoxic PBS liposomes had an effect on glioma migration by partially (or regionally) depleting the slices of microglia.
The microglia in human gliomas is ameboid and thus distinct from the resting microglia found in intact brain (27, 28) . The microglial cells in our slice culture model show a similar morphology and are also not regarded as resting microglia. Interestingly, LPS stimulation of microglia in the slices did not change the rate of GL261 invasion (not shown), indicating that further microglial activation did not alter the interaction with glioma cells.
MMP-2 Expression Correlates with the Presence of Microglia
Zymograms from tissue preparations and from slice culture supernatants revealed that the activity of MMP-2 was directly correlated with the abundance of microglia. In cell culture, we observed that a soluble factor from glioma cells activated MMP-2 activity derived from microglia, but not vice versa. It has been described that glioma can actively attract microglia to migrate into the tumor area (29) and that macrophages have the ability to promote tumor growth and invasion in peripheral tumors by promoting matrix degradation (9) . In a previous in vitro study, activation of MMPs was proposed to induce the protumorigenic activity of microglia in response to gliomas (10) .
Zymograms from supernatants of cultured microglia show virtually no baseline activity of MMP-2. Microglia that were stimulated with GL261-conditioned medium display strong activity of active MMP-2, but lack a band for pro-MMP-2. Cells produced and released the inactive precursor of MMP-2 (pro-MMP-2), which was activated by membranetype matrix metalloprotease (MT-MMP) and is abundant on the plasma membrane of microglia (30) . Therefore, microglia could rapidly convert pro-MMP-2 into MMP-2, explaining the paucity of pro-MMP-2 in the supernatant.
Glioma cells express large amounts of soluble pro-MMP-2, especially at the invading front (25, 26), but they are not able to convert the entire amount of this proenzyme into the active form as a result of insufficient expression of MT-MMP-1 (31) . Therefore, excess pro-MMP-2 produced by gliomas may only be activated after coming into contact with microglial MT-MMP-1, resulting in an additional increase in MMP-2. Thus, microglia may not only release MMP-2, but also may convert the pro-MMP-2 from glioblastoma cells and thereby serve as activators for the protease activity.
In summary, we provide evidence that the net effect of microglia being present in a glioblastoma is protumorigenic. When we prevented microglia from invading the experimental tumors by microglia depletion from brain slices, the invasiveness of the tumor cells significantly decreased. microglial cells, which normally reside within a glioblastoma, may still perform some minor antitumorigenic actions such as inducing growth inhibition or cytotoxicity in neoplastic cells (32) . However, the tumorigenic effects of microglia, like the facilitation of tumor invasion through proteolysis of the extracellular matrix (33, 34) , appears to be preponderant. Our results indicate that improvements in glioblastoma therapy may be achieved by counteracting the intrinsic protumorigenic activity of microglial cells, which are resident in the tumor microenvironment.
